Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
PBM stock price ended at $0.67 on 金曜日, after rising 0.00%
On the latest trading day Jan 16, 2026, the stock price of PBM rose by 0.00%, climbing from $0.69 to $0.67. Throughout the session, the stock experienced a volatility of 13.11%, with prices fluctuating between a daily low of $0.61 and a high of $0.69. Alongside this price increase, trading volume also rose by 36.7K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 506.8K shares were traded, amounting to a market value of approximately $1.2M.